Feasibility and safety profile of posterior retroperitoneoscopic adrenalectomy in high-risk patients
Completed
- Conditions
- E27Other disorders of adrenal gland
- Registration Number
- DRKS00018793
- Lead Sponsor
- Krankenhaus Reinbek St. Adolf-Stift
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 42
Inclusion Criteria
Retroperitoneoscopic adrenalectomy in hospital Reinbek from 2014 to 2018
Exclusion Criteria
No retroperitoneoscopic adrenalectomy in hospital Reinbek
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary endpoint is postoperative complications within 90 days of surgery.
- Secondary Outcome Measures
Name Time Method As a secondary endpoint, the size of the removed adrenal gland was evaluated in the histopathological examination immediately postoperatively.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms underlying posterior retroperitoneoscopic adrenalectomy in adrenal gland disorders?
How does posterior retroperitoneoscopic adrenalectomy compare to open surgery in high-risk adrenal gland patients?
Are there specific biomarkers that identify high-risk patients suitable for retroperitoneoscopic adrenalectomy?
What are the potential adverse events associated with retroperitoneoscopic adrenalectomy in E27 adrenal gland conditions?
What are the current drug classes or combination therapies used for managing E27 adrenal gland disorders alongside surgical interventions?